Pipeline

The only Radiopharmaceutical company achieving
successful commercialization of all new tracers in Korea

New Drug Development Strategy for Radiopharmaceuticals

Pipeline

FES

- Korea’s first Radiopharmaceutical diagnostic tracer for breast cancer in the market

- Medical imaging agent to detect metastatic breast cancer and differentiate the Estrogen receptor status

Rights & Permissions / Sales Acquire the rights for Korean domestic market and secure the overseas licensing rights Drug classification Diagnosis of breast cancer
Dates (Approval/Agreement) Acquired NDA approval on Nov. 2019 Remarks
  • Manufacturing technology joint development with Asan Medical Center
  • First-In-Class
  • In negotiation with USA, EU, Australia, China and Japan
F-DOPA

- Diagnosis of brain tumors that are undetectable using FDG

- World’s first stable neutralization manufacturing technology

Rights & Permissions / Sales NDA in Korea and international licensing & commercialization Drug classification Diagnosis of brain tumor
Dates (Approval/Agreement) Acquired NDA approval on Oct. 2019 Remarks
  • Manufacturing technology joint development with Asan Medical Center
  • Best-in-class with exclusive rights
FACBC

- Korea’s first Radiopharmaceutical diagnostic tracer for prostate cancer in the market

- Open a new era for the diagnosis of metastatic and recurrent prostate cancer

Rights & Permissions / Sales For international market Drug classification Diagnosis of prostate cancer
Dates (Approval/Agreement) June 24, 2019 – Exclusive licensing agreement signed
(Approved by US FDA and EMA)
Remarks
  • First-in-class with exclusive rights
  • Licensed in from Japan NMP
  • Targets the first-mover in the prostate cancer diagnostic market
  • Overlapping effects after new drug approval
Solucin(177Lu-DOTATOC)

- Developed and launched therapeutic Radiopharmaceutical for the first time in the country

- Korea’s first Radiopharmaceutical therapy for Neuroendocrine tumor in the market

Rights & Permissions / Sales For approval in Korea Drug classification Gastroenteropancreatic Neuroendocrine Tumor Treatment
Dates (Approval/Agreement) August 30, 2019 – Exclusive licensing agreement signed Remarks
  • Phase II clinical trial in South Korea in 2020
  • Commercialization in January 2020
  • Compassionate Use Program for non-clinical trial subjects

그누보드5
Address 4F, 47, Kyonggidae-ro, Seodaemun-gu, Seoul, Republic of Korea [03752]
Tel 02 332 4868 Fax 02 323 3437

Copyright © 2019 Duchembio, Inc. All Rights Reserved